Correlation Between Viracta Therapeutics and Zymeworks Common

Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and Zymeworks Common at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and Zymeworks Common into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viracta Therapeutics and Zymeworks Common Stock, you can compare the effects of market volatilities on Viracta Therapeutics and Zymeworks Common and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of Zymeworks Common. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and Zymeworks Common.

Diversification Opportunities for Viracta Therapeutics and Zymeworks Common

-0.67

Correlation Coefficient

Viracta Therapeutics  Zymeworks Common

Excellent diversification

The 3 months correlation between Viracta and Zymeworks is -0.67. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and Zymeworks Common Stock in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zymeworks Common Stock and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with Zymeworks Common. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zymeworks Common Stock has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and Zymeworks Common go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and Zymeworks Common

Given the investment horizon of 90 days Viracta Therapeutics is expected to under-perform the Zymeworks Common. In addition to that, Viracta Therapeutics is 1.63 times more volatile than Zymeworks Common Stock. It trades about -0.08 of its total potential returns per unit of risk. Zymeworks Common Stock is currently generating about 0.05 per unit of volatility. If you would invest  1,218  in Zymeworks Common Stock on September 12, 2024 and sell it today you would earn a total of  88.00  from holding Zymeworks Common Stock or generate 7.22% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Viracta Therapeutics  vs.  Zymeworks Common Stock

Viracta Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Zymeworks Common Stock

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Zymeworks Common Stock are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating primary indicators, Zymeworks Common may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Viracta Therapeutics and Zymeworks Common

The main advantage of trading using opposite Viracta Therapeutics and Zymeworks Common positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, Zymeworks Common can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zymeworks Common will offset losses from the drop in Zymeworks Common's long position.

The idea behind Viracta Therapeutics and Zymeworks Common Stock pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.